Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
1999
Cardiac Toxicity of HMR-1826, a New Doxorubicin Prodrug
publication
Evidence: moderate
Author Information
Author(s): Platel D, Bonoron-Adèle S, Dix R K, Robert J
Primary Institution: Institut Bergonié
Hypothesis
HMR-1826, a novel prodrug of doxorubicin, will have lower cardiotoxicity compared to doxorubicin and Doxil.
Conclusion
HMR-1826 is significantly less cardiotoxic than doxorubicin, making it a potentially safer option for cancer treatment.
Supporting Evidence
- HMR-1826 was administered intravenously every other day for 11 days.
- Doxorubicin strongly decreased cardiac function at higher doses.
- HMR-1826 only induced significant cardiac alterations at the highest dose used.
Takeaway
This study found that a new drug, HMR-1826, is much safer for the heart than an older cancer drug called doxorubicin.
Methodology
The study used isolated perfused rat hearts to compare the cardiac effects of HMR-1826, doxorubicin, and Doxil.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website